The Global Initiative for Asthma’s report, Global Strategy for Asthma Management and Prevention, is recommending allergy immunotherapy as a treatment option.
"We are extremely pleased to see the recognition of ACARIZAX clinical evidence in the management of asthma,” Henrik Jacobi, executive vice president of research and development at ALK, said in a statement. “This confirms our long-held conviction that allergy immunotherapy has an important role to play in the treatment of allergic asthma, a belief confirmed by the unprecedented clinical development program for ACARIZAX, currently the only HDM SLIT-tablet indicated for use in patients with house dust mite allergic asthma that is not well controlled."
The company will continue to seek evidence for the benefits of allergy immunotherapy treatment.
"ALK is committed to gathering further evidence to support the wider recognition of allergy immunotherapy as a treatment option for asthma, and to investigating the potential role for allergy immunotherapy in preventing the onset of asthma,” Jacobi said.
ALK’s ACARIZAX is approved in 12 European countries and Australia to treat HDM allergic asthma.
Alerts Sign-up